Do you want to read an article? Please log in or register.
ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors
Leukemia
Related content
Leukemia
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY
Leuk Lymphoma
Mauro MJ, Hehlmann R, Williams LA, Goldberg SL, Michallet M, Gambacorti-Passerini C, Tang D, DeGutis IS, McBride A, Parsons L, Montelongo M, Cortes JE
doi: 10.1080/10428194.2025.2495369
Leukemia
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results
Leukemia
Rea D, Kyrcz-Krzemien S, Sportoletti P, Mayer J, Illes A, Angona Figueras A, Kiani A, Charbonnier A, Marinakis T, Stenke L, Steegmann JL, Saglio G, Hellmann A, Niederwieser D, Schuld P, Rosti G
doi: 10.1038/s41375-025-02847-5
Leukemia
Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis
Leuk Lymphoma
Majrashi A, Shantsila A, Gue YX, Williams S, Lip GYH, Pettitt AR
doi: 10.1080/10428194.2026.2653123
Leukemia
Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study
Br J Haematol
Costa A, Scalzulli E, Carmosino I, Bisegna ML, Laganà A, Ielo C, Cappelli L, Martelli M, Breccia M
doi: 10.1111/bjh.70418
Leukemia
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
J Clin Oncol
Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Mátrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM
doi: 10.1200/JCO-25-00166
Leukemia
Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib
Haematologica
Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stölzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kröger N
doi: 10.3324/haematol.2025.300176
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Leukemia
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint
Leukemia
Castagnetti F, Breccia M, Abruzzese E, Bassan R, Binotto G, Bonifacio M, Caocci G, Capodanno I, Cavazzini F, Cimino G, Fazi P, Gozzini A, Iurlo A, Janssen JJWM, Lunghi M, Marasca R, Martino B, Messina M, Muriano F, Paoloni F, Piciocchi A, Rosti G, Russo Rossi A, Saglio G, Sica S, Soverini S, Tafuri A, Vallisa D, Westerweel PE, Pane F
doi: 10.1038/s41375-025-02796-z
RECOMMENDED
Head and Neck Cancer
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Liu G, Abrahami D, Ramachandran P, Messina R, Rifi N, Yang H, Chai X, Li B, Ramaswamy K, Iyengar P, Pennell NA, Shaw AT
doi: 10.1016/j.lungcan.2025.108858